YDES
$5.46
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
Recent News
Breeze Holdings Acquisition (YDES) Rises 31% Over the Past Month
In recent events, YD Bio Limited's addition to the NASDAQ Composite Index has elevated the company's market standing, while Breeze Holdings Acquisition (YDES) has seen a 31% price rise over the past month. This surge coincides with significant developments, including a business combination with Taiwan-based YD Biopharma, signaling a move to strengthen their presence in the biopharmaceutical industry. These corporate actions place the company's recent performance against the backdrop of a...
Top Midday Gainers
Professional Diversity Network (IPDN) said Friday it signed a non-binding memorandum of understandin